What question did this study set out to answer?

This review examines the pharmacological differences between rivaroxaban and apixaban in patients with short bowel syndrome (SBS).

March 1, 2026

Rivaroxaban vs. Apixaban in Short bowel syndrome: a focused clinical Pharmacology review.

Key Points

This review examines the pharmacological differences between rivaroxaban and apixaban in patients with short bowel syndrome (SBS).
Analysis of drug absorption characteristics and pharmacokinetics in short bowel syndrome.
Comparison of rivaroxaban and apixaban's effectiveness based on residual bowel length.
Review of recommendations for monitoring anti-Xa levels to evaluate absorption.
Rivaroxaban shows food-dependent absorption, making it more sensitive to bowel length changes.
Apixaban has food-independent absorption, providing more stable pharmacokinetics in SBS.
Both medications can be effective, with apixaban being more reliable for adjusted dosing.

Abstract

Rivaroxaban exhibits food-dependent, dissolution-limited absorption in the stomach and proximal small intestine, and systemic exposure appears more sensitive to residual bowel length. Apixaban demonstrates linear, food-independent pharmacokinetics and generally preserved absorption in stable SBS, enabling concentration-guided dose adjustment when needed. Both agents can be effective in selected patients, but apixaban offers greater pharmacokinetic robustness in the context of altered intestinal anatomy or inconsistent oral intake. Early anti-Xa - based monitoring is advisable for either drug to confirm adequate absorption.

AI에게 질문

Bookmark

Cite This Study

Hronová et al. (Fri,) studied this question.

synapsesocial.com/papers/69a3d8b8ec16d51705d2fdd6 https://doi.org/https://doi.org/10.1080/17425255.2026.2637736

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark